产品
编 号：F744981
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1422527-84-1
产品详情
生物活性：
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
体内研究：
Tafasitamab (SC，第 1 天一次，2.5 μg/kg) 抑制播散性 BL 小鼠异种移植肿瘤模型中的淋巴瘤生长。Animal Model:Disseminated Raji model.
Dosage:2.5 μg/kg
Administration:Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:Showed antitumor activity in disseminated Raji model.
Animal Model:Disseminated Ramos model.
Dosage:10 mg/kg
Administration:Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of10 mg/kg)
Result:Showed antitumor activity in disseminated Ramos model.
体外研究：
Tafasitamab (XmAb5574) 以 E/T 比率依赖性方式诱导对 Mino 和 Jeko (MCL) 细胞系的细胞毒性。Tafasitamab (XmAb5574) 增加 ADCP 和抗增殖活性。Tafasitamab (XmAb5574) 可增强半胱天冬酶诱导细胞凋亡引起的抗增殖细胞凋亡活性。
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
体内研究：
Tafasitamab (SC，第 1 天一次，2.5 μg/kg) 抑制播散性 BL 小鼠异种移植肿瘤模型中的淋巴瘤生长。Animal Model:Disseminated Raji model.
Dosage:2.5 μg/kg
Administration:Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:Showed antitumor activity in disseminated Raji model.
Animal Model:Disseminated Ramos model.
Dosage:10 mg/kg
Administration:Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of10 mg/kg)
Result:Showed antitumor activity in disseminated Ramos model.
体外研究：
Tafasitamab (XmAb5574) 以 E/T 比率依赖性方式诱导对 Mino 和 Jeko (MCL) 细胞系的细胞毒性。Tafasitamab (XmAb5574) 增加 ADCP 和抗增殖活性。Tafasitamab (XmAb5574) 可增强半胱天冬酶诱导细胞凋亡引起的抗增殖细胞凋亡活性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备